Kitov Pharma (KTOV) Announces Results Showing NT-219 Enhanced Efficacy of Keytruda in Immune-Oncology Preclinical Model
Tweet Send to a Friend
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) today announced results of a pre-clinical study demonstrating that NT-219, the lead drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
